Welcome to our dedicated page for Clarivate Plc SEC filings (Ticker: CLVT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clarivate Plc filings document the financial reporting, governance and capital structure of a Jersey-incorporated public company that provides enriched data, analytics, workflow solutions and expert services across Academia & Government, Intellectual Property, and Life Sciences & Healthcare. Current reports furnish quarterly and annual earnings releases, supplemental revenue, earnings and guidance materials, and Regulation FD presentations.
The company's SEC records also cover proxy governance and executive compensation matters, including annual meeting disclosures and executive severance plan terms. Other filings describe financing arrangements involving subsidiaries, credit agreement amendments, senior secured note redemption and satisfaction and discharge, and related material-event disclosures under the Exchange Act.
CLARIVATE PLC President, A&G Bar Veinstein received a large equity award. He was granted 377,358 Ordinary Shares on a non-cash basis, classified as a grant or award acquisition. This compensation-related grant increased his direct holdings to 1,263,016 Ordinary Shares, aligning more of his pay with the company’s share performance.
Clarivate plc Executive Vice President and CFO Jonathan Mark Collins reported several non-market changes in his CLVT shareholdings. He received a grant or award of 471,698 Ordinary Shares, boosting his equity-based compensation. On the same date, 43,987 shares were withheld at $2.5700 per share to cover taxes due upon the vesting of restricted share units, which is an administrative disposition rather than an open-market sale.
Separately, pursuant to a divorce settlement, 35,741 shares were transferred for no consideration to his former spouse, and he no longer reports beneficial ownership of those shares. After these transactions, Collins directly holds 1,145,554 Ordinary Shares of Clarivate.
Mourad Maroun S. reported acquisition or exercise transactions in this Form 4 filing.
Clarivate PLC executive Mourad Maroun S., President, IP, received a grant of 377,358 Ordinary Shares as a stock award at no cost. Following this award, his direct holdings increased to 916,926 Ordinary Shares. The filing also shows 105,000 Ordinary Shares held indirectly through his spouse.
CLARIVATE PLC President, LS&H Henry Levy received a grant of 377,358 Ordinary Shares on March 15, 2026 at no cost, increasing his direct equity stake as compensation. Of these, 35,402 shares were withheld at $2.57 per share to satisfy tax obligations upon restricted share unit vesting. Following the grant and tax withholding, he directly owns 1,003,266 Ordinary Shares, reflecting routine equity compensation activity rather than open-market buying or selling.
Clarivate PLC President, LS&H Henry Levy reported a tax-related share disposition. On the vesting of restricted share units, 37,342 ordinary shares were withheld at a price of $2.30 per share to cover taxes, according to the Form 4. After this tax-withholding disposition, Levy directly holds 661,310 ordinary shares.
Clarivate PLC Senior VP, Finance/CAO Michael M. Easton reported equity compensation activity and related tax withholding in company ordinary shares. On February 18, 2026, he acquired 4,266 ordinary shares through a grant or award, tied to performance share units granted in 2023 that remain subject to time-based vesting terms.
On March 1, 2026, he disposed of 27,136 shares and 704 shares at $2.30 per share through tax-withholding dispositions when performance share units and restricted share units vested. Following these transactions, he directly held 474,190 ordinary shares. The filing notes it was submitted late due to inadvertent administrative oversight.
Clarivate PLC executive William E. Graff reported routine equity compensation activity and related tax withholding. On February 18, 2026, he acquired 4,266 Ordinary Shares at $0.00 per share as a grant tied to performance share units granted in 2023, which remain subject to time-based vesting terms.
On March 1, 2026, he disposed of 491 Ordinary Shares and 20,336 Ordinary Shares at $2.30 per share to cover tax liabilities upon vesting of performance and restricted share units. After these transactions, he directly owned 603,246 Ordinary Shares. The filing notes it was submitted late due to inadvertent administrative oversight.
Clarivate plc Executive Vice President and CFO Jonathan Mark Collins reported a tax-withholding disposition of ordinary shares tied to equity compensation. On the vesting of restricted share units, 41,640 ordinary shares were withheld on March 1, 2026 at $2.30 per share to cover tax obligations, coded as a tax-liability payment rather than an open-market sale. After this non-market transaction, his directly held stake was 753,584 ordinary shares.
Clarivate Plc files its annual report describing a global information services business focused on transformative intelligence across Academia & Government, Intellectual Property, and Life Sciences & Healthcare. The company emphasizes AI-enabled research assistants and agents embedded in its platforms to enhance insight generation and workflow automation.
About 83% of 2025 revenue came from subscription-based and re-occurring arrangements, supporting stable cash flows. Clarivate reports more than 12,000 employees in over 40 countries and strong renewal rates above 90%. As of June 30, 2025, non‑affiliate market value of ordinary shares was approximately $1.3 billion, with 640,698,582 shares outstanding as of January 31, 2026.
The report details a Value Creation Plan centered on scaling AI innovation, strengthening commercial execution, expanding margins, and shifting from transactional sales to subscriptions. Extensive risk disclosures highlight dependence on third‑party data, rising free information sources, AI governance and regulation, cybersecurity, international operations, and significant use of proprietary and third‑party intellectual property.
Clarivate Plc reported softer 2025 revenue but stronger cash generation and a much smaller net loss, while advancing a major portfolio reshaping. Full-year revenue was $2,455.2 million, down 4.0%, as planned divestitures and weaker transactional activity offset 0.6% recurring organic growth. The net loss narrowed sharply to $201.1 million from $636.7 million, and Adjusted EBITDA slipped to $1,001.8 million from $1,060.4 million.
Free cash flow grew to $365.3 million, helped by disciplined capital spending, and the company repurchased 56.0 million shares in 2025 and reduced total debt to $4,469.9 million. Management launched a sale process for the Life Sciences & Healthcare business and expects 2026 revenue of $2.30–$2.42 billion, with Adjusted EBITDA of $980 million–$1.04 billion, Adjusted diluted EPS of $0.70–$0.80, and free cash flow of $365–$435 million, implying modest organic ACV and recurring revenue growth alongside margin expansion.